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Abstract
Metformin was approved for the treatment of Type 2 Diabetes Mellitus in 1958 
for UK, in 1972 for Canada and in 1995 by FDA in USA. Metformin is the drug of 
choice for patients who are obese and have type 2 diabetes mellitus. Though metfor-
min was at first proven to treat hyperglycemia, many other uses of metformin are 
proven to be effective. It is also used for gestational diabetes mellitus, obesity, hyper 
secretion of ovarian androgen, poly-cystic ovary syndrome (PCOS), anti-psychotic 
therapy induced weight gain, cancer treatment and anti-aging. Metformin causes 
a decrease in appetite thus known to act on obesity. The other action of metformin 
is reduction of circulating levels of insulin and insulin like growth factor 1 (IGF-1) 
which is associated with anticancer action. There are ongoing researches about the 
effect of metformin on anti-aging properties and proved that metformin is linked 
with anti-aging factors. Three main factors that are related with aging are oxida-
tion, glaciation and methylation. Metformin as all drugs, have unwanted effects as 
well. Many side effects of metformin are considered mild where lactic acidosis and 
vitamin B12 deficiency happens to be the major.
Keywords: metformin uses, diabetes mellitus, obesity, poly-cystic ovary syndrome, 
cancer
1. Introduction
1.1 Pros (uses) of metformin
Metformin, the most common drug used to treat type 2 diabetes, approved by 
U.S. Food Drug Administration (US-FDA) (1), belongs to a class of drugs called 
biguanides with a guanidine and galegine connection. Metformin was approved for 
treatment of Type 2 Diabetes Mellitus in 1958 for UK [1], 1972 for Canada [2] and 
1995 by FDA in USA [1, 3].
Metformin (1,1-dimethyl biguanide hydrochloride) was synthesized in 1920’s. 
Since then, the drug became the first choice to treat type 2 diabetes due to its 
remarkable ability to decrease plasma glucose levels [4–6]. It acts by reducing 
the glucose made by liver, decreasing the amount glucose that body absorbs and 
increasing the effect of insulin in the body [7].
In recent years, studies have shown many unexpected effective roles of 
metformin that exerts strong effect on cardiovascular disease (CVD) [8], cancers 
[9, 10], neurodegenerative diseases [11], liver diseases [12], obesity [13, 14], and 
renal diseases [15], hypersecretion of ovarian androgens, poly-cystic ovary syn-
drome (PCOS), anti-psychotic therapy induced weight gain, and anti-aging [16].  
Metformin
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The agent also offers neuro protection that may reduce the risk of dementia and 
stroke [17].
1.1.1 Metformin in diabetes
Several studies and clinical trials have confirmed that metformin mono therapy 
or combination therapy with other glucose-lowering drugs is successful in treating 
type 2 diabetes. Metformin is the drug of choice for diabetic patients who are obese 
and have type 2 diabetes mellitus.
Type 2 diabetes coexists with insulin resistance and leads to extremely high 
blood sugar levels. Metformin lowers blood sugar, preventing permanent organ 
damage, which in due course could lead to dysfunction and failure [18, 19]. 
Metformin exerts its anti-hyperglycemic effects through AMP which initiates the 
uptake of sugar from the blood into muscles.
Metformin exerts its anti-hyperglycemic effects by suppressing hepatic glucose 
production through AMPK dependent [20, 21] or -independent pathways [22, 23].
Metformin increases AMPK that leads to more sugar being taken from the blood 
into tissues, thus lowering the blood sugar level [24].
It is used in case of insulin resistance as it works by decreasing hepatic glucose 
production, decreasing peripheral insulin resistance and improving insulin sensi-
tivity thereby increasing peripheral glucose uptake and utilization. Metformin does 
not produce hypoglycaemia and does not cause hyperinsulinemia in normal patients 
or in patients with type 2 diabetes. Insulin secretion remains unchanged whereas 
fasting insulin levels and daylong plasma insulin response may decrease with 
metformin therapy [25].
On the other hand, metformin may reduce blood sugar by inhibiting the produc-
tion of new glucose (gluconeogenesis) from non-carbohydrates such as lactate, 
glycerol, and some amino acids [23]. Metformin inhibits gluconeogenesis through 
AMPK-dependent activation of small hetero dimer partner (SHP) and inhibition 
of phosphorylation of CREB binding protein (CBP) [26], thereby suppressing the 
expression of gluconeogenic genes, such as G6Pase (glucose 6 phosphatase), PEPCK 
(phosphoenolpyruvate carboxykinase), and PC (pyruvate carboxylase) [27].
Studies also suggest that metformin could enhance GLUT1 (glucose transporter 
1) mediated glucose transport into hepatocytes by activating IRS2 (insulin receptor 
substrate two), decreasing plasma glucose levels [28].
Besides decreasing liver glucose production, metformin also decreases glucose 
levels through increasing (i) GLUT4 (glucose transporter 4) mediated glucose 
uptake in skeletal muscles [29] and (ii) absorption of glucose in the intestines 
[30]. Metformin also stimulates glucagon-like-peptide-1 (GLP-1) release, thereby 
improving insulin secretion and reducing plasma glucose levels [31]. The molecular 
mechanism of metformin in hepatic gluconeogenesis and glucose production is 
shown in Figure 1.
A clinical trial conducted on over 3,000 people who were at risk of developing 
type 2 diabetes showed that those people treated with metformin had a 31% lower 
occurrence of type 2 diabetes compared to the placebo group [34].
1.1.2 Metformin in gestational diabetes
Gestational diabetes mellitus (GDM) is the most common medical complication 
of pregnancy which is associated with insulin resistance (IR) and hyperinsulinemia 
that may predispose some women to develop diabetes. Gestational diabetes has been 
defined as any degree of glucose intolerance with an onset, or first recognition dur-
ing pregnancy [35]. In 2013, the World Health Organization (WHO) recommended 
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that hyperglycemia first detected during pregnancy be classified as either ‘diabetes 
mellitus (DM) in pregnancy’ or ‘GDM’ [36]. GDM is associated with short- and 
long-term sequelae on both, mother and offspring [37, 38].
During normal pregnancy, around the mid-pregnancy, a progressive insulin 
resistance develops that progresses during the third trimester. In early pregnancy, 
insulin secretion increases, while insulin sensitivity remain unchanged, decreased 
or increased whereas in mid pregnancy, insulin sensitivity declines progressively 
and worsens during the rest of the pregnancy, being worst in the late third trimes-
ter, which rebounds with the delivery of the placenta. Therefore, GDM usually 
develops in the late second trimester and disappears, instantly, post-delivery [39].
For GDM, lifestyle interventions such as daily exercise, medical nutrition 
therapy is the initial treatment while, metformin, the oral hypoglycemic agent is 
being considered as a substitute to insulin. The rationale behind using metformin 
in gestational and pre-existing diabetes during pregnancy is as metformin increases 
insulin sensitivity, reduces hepatic glucogeneogenesis and enhances peripheral 
glucose uptake, resulting in lowering of blood glucose with minimal risk of mater-
nal hypoglycemia and weight gain [40].
Although, metformin has been shown to pass freely across the placenta [41], 
there are no reported adverse side effects to the fetus when it is used to treat women 
with infertility caused by poly-cystic ovary syndrome (PCOS) [42, 43]. Metformin 
is classified as a category B drug, which implies that there is no confirmation of 
animal or fetal toxicity or teratogenicity. The study of metformin in pregnancy 
revealed that the use of metformin in women with GDM was not associated with 
increased risk of congenital anomalies, or maternal and neonatal complications 
compared to insulin, except for higher rates of preterm labour [44].
Results of systematic review and meta-analysis had shown that metformin 
is better than insulin in reducing, maternal weight gain during pregnancy 
and the frequency of pregnancy induced hypertension, with no changes in 
the frequency of hypoglycemia and pre-eclampsia [45]. In addition, random-
ized controlled trials (RCT) suggest that metformin could be used to treat or 
Figure 1. 
Metformin in hepatic gluconeogenesis and glucose production. Metformin acts primarily to suppress glucose 
production in the liver. While metformin’s mechanism(s) of action remain controversial, current evidence 




prevent pre-eclampsia [46]. Metformin is considered as the first-line drug in 
the management of type 2 diabetes due to its efficacy, tolerability and safety in 
non-pregnant individuals.
1.1.3 Metformin in polycystic ovary syndrome
Poly-cystic ovarian syndrome (PCOS) is a hormonal disorder often aggravated 
by obesity and insulin resistance. PCOS is an endocrine-metabolic dysfunction 
among 5–10% of women in reproductive age which is associated with metabolic 
disturbances that have a high impact in cardio metabolic diseases, such as insulin  
resistance [47–49].
PCOS is characterized by menstrual irregularities, low fertility, obesity and high 
blood levels of male hormones in reproductive aged women [50]. PCOS confirms 
insulin resistance which leads to the hypothesis of a pre-diabetic state with glucose 
intolerance, gestational diabetes mellitus and evident diabetes. Several studies show 
that insulin resistance stimulates the ovaries to produce male hormones, i.e., andro-
gens. This causes stigmata of androgen excess such as hirsutism and acne. Metformin 
increases insulin sensitivity and decreases the production of ovarian androgen 
thereby normalizing the hormone levels, stabilizes menstrual irregularities and 
improves fertility and ovulation. It also directly inhibits the androgen production [51].
Metformin treats PCOS symptoms, such as irregular ovulation or menstrual 
cycles, and the excess of insulin in the body. It has also been made known to treat 
PCOS symptoms by reducing body mass index (BMI) and testosterone levels. 
Furthermore, metformin assists fertility and increases the chance of successful 
pregnancy and reduces the risk of early miscarriage, gestational diabetes, and 
inflammation associated with PCOS. Metformin is thus used as the drug of choice 
for the treatment of PCOS. More to that, metformin helps mothers carry their baby 
to full term [51, 52]. Metformin is strongly recommended in patients with metabolic 
syndrome and obesity [51].
1.1.4 Metformin in obesity
Obesity is a chronic disease accompanied with metabolic syndromes, such as 
diabetes, fatty liver diseases, and cardiovascular diseases (CVDs). Obesity is caused 
by an imbalance between energy intake and expenditure [53].
Metformin happens to be one of the drugs available for the treatment of obe-
sity. Metformin acts on obesity by decreasing the appetite and reduced BMI levels. 
Metformin contains a primary anorectic factor which reduces the appetite. Leptin 
levels were found to be decreased on taking metformin. Moreover, glucagon like 
peptide-1 levels rise significantly on taking metformin. This promotes weight loss. It 
was observed that adults with severe obesity lost weight more significantly than mildly 
obese patients [54]. Metformin exerts its anti-obesity effects through increasing mito-
chondrial biogenesis, decreasing fatty acid uptake, and stimulating thermogenesis [55].
It acts by promoting sugar dysplasia restrains and reducing inhibition caused by 
insulin-induced expression of the glucose transporter protein, thus increasing glucose 
utilization [56]. Metformin is effective in reducing body weight and improving insulin 
sensitivity in adults, and is used to treat adolescents who are overweight or obese and 
unresponsive to changes in lifestyle or who present with insulin resistance [57]. Many 
studies support that metformin can promote weight loss in overweight or obesity 
patients [58, 59]. Based on the reports it is understood that clinical trials supports the 
efficacy and safety profiles of metformin in diabetes and weight gain prevention [60].
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1.1.5 Metformin in medication induced weight gain
Studies have shown that use of antipsychotics increase the risk of weight gain, 
dyslipidemia and diabetes. Weight gain and abdominal adiposity which is directly 
associated with insulin resistance, dyslipidemia and risk of diabetes may be induced 
by second generation antipsychotics [61, 62]. Stimulation of appetite, reducing 
physical activity and impairing metabolic regulation is the mechanism of antipsy-
chotics induced weight gain [63].
Metformin aids in weight loss. Drug induced weight gain can be reduced by 
metformin. It assists in reduction of weight for those who gain 10% of body weight 
than pre-treatment [63]. Metformin contains an anorectic factor and facilitates less 
hunger. This also aids in decreased appetite. Metformin causes decreased leptin 
levels, thus suppresses appetite. Metformin also increases the GLP-1 levels which 
enhances weight loss. Thus, metformin with lifestyle changes is effective in the 
treatment of weight gain induced by antipsychotics.
1.1.6 Metformin in cancer
New studies have shown that metformin is effective in killing cancer cells. In tri-
als, people undergoing chemotherapy alone saw their cancer return, while for those 
on chemo and metformin, their tumors disappeared. Research has shown that those 
taking metformin are less likely to develop certain cancers. Metformin has been 
found to improve cancer prognosis as it inhibits cancer cell growth and prolifera-
tion. Evidence points that metformin inhibits growth, survival, and metastasis of 
different types of tumor cells, including those from breast, liver, bone, pancreas, 
endometrial, colorectal, kidney, and lung cancers [64].
Metformin prevented the growth and spreading of certain cancers in patients 
with type 2 diabetes. This proposed mechanism is through a known tumor-suppres-
sant gene (LKB1), which activates AMPK. Metformin shows anticancer properties 
by direct and indirect regulation of cells’ metabolism. The direct effects are medi-
ated by AMPK dependent and -independent pathways. (i) Metformin activates 
AMPK, which leads to the inhibition of mTOR signaling, and thereby disturbs the 
protein synthesis, and suppresses the cell growth and proliferation [65]. As an anti-
diabetic drug, metformin decreases plasma glucose levels, thereby inhibiting cancer 
cell proliferation and survival [66].
Other studies reported that metformin could activate the immune response 
against cancer cells [67] or decrease NF-kB (nuclear factor-kB) activity, which 
results in a reduction in the secretion of pro-inflammatory cytokines [68].
Metformin activates AMPK and then induces p53 phosphorylation to prevent 
cell invasion and metastasis [69].
The different mechanisms antitumor action has been proposed which involves 
the following: (a) the activation of adenosine monophosphate kinase, (b) modula-
tion of adenosine A1 receptor (ADORA), (c) reduction in insulin/insulin growth 
factors, and (d) inhibition of endogenous reactive oxygen species (ROS); and its 
resultant damage to deoxyribonucleic acid (DNA) molecule is another paramount 
antitumor mechanism [70].
Metformin reduces the proliferation of cancer cells and the possibility of 
malignancies in different types of cancer, including gastric carcinoma, pancreatic 
cancer, uterine cancer, medullary thyroid cancer [71]. Figure 2 shows the mecha-





Breast cancer (BC) is one of the most common malignancies occurring in 
females. Cellular glucose metabolism is linked tightly with the proliferation and 
development of breast cancer. Several studies suggested that metformin reduces 
Figure 2. 
Mechanism of metformin in Cancer. The anticancer activity of metformin is associated with direct and indirect 
effects of the drug. The direct insulin-independent effects of metformin are mediated by activation of AMPK 
and a reduction in mTOR signaling and protein synthesis in cancer cells [72].
Figure 3. 
Direct and indirect effects of metformin on cancer. Metformin activates AMPK leading to stabilization of 
TSC2 and inhibition of mTORC1 signaling and protein synthesis. Metformin can also directly target mTOR 
independently of AMPK and TSC2 [73].
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the incidence of breast cancer in type 2 diabetes patients [74]. Cancer cells show 
enhanced glucose uptake and metabolism and prefer glycolysis. The noted specialty 
of metformin is to decrease glucose levels, thereby limiting the availability of 
energy for cancer cells. Metformin decreases FAS expression which is an essential 
component of the fatty acid synthesis pathway, therefore affecting the survival of 
cancer cells.
1.1.6.2 Blood cancer
Leukemia comprises 2.8% of all cancers and 3.4% of cancer-related deaths world-
wide. The aberrant activation of the PI3K/AKT/mTOR pathway is one of the most 
common biochemical features of leukemia [75]. Metformin inhibits AKT/mTOR sig-
naling, which is an effective approach to treat leukemia. Metformin plays a beneficial 
role in human lymphoma by inhibiting mTOR signaling without the involvement of 
AKT, and the suppression of mTOR subsequently leads to the suppression of growth 
of B cells and T cells [76].
1.1.6.3 Colorectal cancer (CRC)
CRC is also one of the most common cancers in the world. In 2004, relationship 
between metformin and CRC was demonstrated [77]. Metformin may exert its 
pharmacodynamic effects through the gut-brain-liver axis, but these mechanisms 
require further exploration. In the intestine, metformin increases glucose uptake 
and lactate concentrations. Administration of metformin increases the bile acid 
pool in the intestine that may affect GLP-1 secretion and cholesterol levels. In addi-
tion, metformin changes the microbiome, affecting the regulation of metabolism, 
such as glucose homeostasis, lipid metabolism, and energy metabolism [78]. These 
changes inhibits the development and progress of CRC.
1.1.6.4 Bone cancers
Compared with cancers initiating in bone tissue itself, invasion of metastatic 
cancers, especially breast, lung, and prostate cancers, into bones is more common 
[79]. All types of bone cancers influence the osteolytic process, and osteoblastic 
metastases occur through osteoclast activation or stimulant factors which are 
responsible for osteoblastic proliferation, differentiation, and formation [80].
1.1.6.5 Endometrial cancer
Metabolic syndrome like obesity and hyperglycemia is related to the develop-
ment of endometrial cancer. Metformin is an effective anti-diabetic drug, studies 
have demonstrated the beneficial effect of metformin on endometrial cancer 
development by the mechanisms involving the mitochondrial OXPHOS suppression 
and AMPK activation which subsequently inhibit a variety of metabolic pathways, 
including STAT3, ZEB-1, ACC, mTOR, and IGF-1 [81].
1.1.6.6 Melanoma
Melanoma is the most aggressive skin cancer and is responsible for almost 80% 
of the skin cancer-related deaths. Due to its strong invasive ability, melanoma often 
metastasizes to the lymph nodes, liver, lungs, and even the central nervous system 
[82]. Metformin can induce cell cycle arrest in the G0–G1 phase in melanoma cells. 
Another study indicated that metformin can attenuate melanoma growth and 
Metformin
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metastasis through inhibiting the expression of TRB3 (tribbles pseudokinase 3) 
in non-diabetic and diabetic mouse models [83]. Because of the activation effect 
of AMPK, metformin could influence melanoma cell death and proliferation and 
the tumor microenvironment. It will be interesting to investigate the effects of 
combination treatment of metformin with current therapies or other drugs to treat 
melanoma.
1.1.7 Metformin in aging
Aging is considered unavoidable and is modulated by genetic and dietary 
factors. The declining ability to regenerate damaged tissue and the deterioration in 
homeostatic processes are considered as biological features of aging [84]. Usually, 
the primary causes foraging are DNA damage and autophagy. Aging is a result of 
DNA damage, which can be induced by ROS, alkylation, hydrolysis, chemicals, 
and ultraviolet and other radiation [85]. Trials have shown metformin’s efficacy 
in reducing the effects of aging, such as decreasing age-related illnesses, problems 
with cognitive function, and morbidity [86].
Metformin slows down aging and reduces the incidence of aging-related diseases 
such as neurodegenerative disease and cancer in humans. In spite of its widespread 
use, the mechanisms by which metformin exerts favorable effects on aging remain 
largely unknown [87]. The mechanisms by which metformin affects the aging 
process are partly dependent on the regulation of glucose metabolism. By inhibiting 
mitochondrial complex I, metformin reduces endogenous production of ROS and 
subsequently decreases DNA damage [88].
By activating AMPK, metformin is able to inhibit NF-kB signaling and attenu-
ate cell inflammation [89]. Metformin also leads to decreased insulin levels, and 
suppresses IGF-1 signaling and mTOR signaling, resulting in suppression of 
inflammation and autophagy, which is beneficial to the aging process [90]. Besides, 
metformin was shown to have a function in the regulation of the microbiome, 
which may be another way to affect aging [91]. There are three main factors that are 
related with aging. They are oxidation, glycation and methylation. There is evidence 
that metformin acts as an anti-aging agent. It helps slow the rate of aging and retain 
youth characteristics for a longer period of time than compared to non-metformin 
users. There are ongoing research about the effect of metformin on anti-aging prop-
erties. Researches have proved that metformin is linked with anti-aging factors [92].
There are two mechanisms to describe aging. First one is ROS theory, i.e., 
reactive oxygen species [93]. The ROS theory explains that by products of oxidative 
phosphorylation are reactive oxygen species, i.e., free radicals. The free radicals 
increase significantly and damage other cells and organs. The ROS leads to DNA 
damage [64].
The second mechanism is TOR theory. Cellular pathway like IGF-1 axis, MAPK, 
AKT, PI3K stimulated by mitogens, growth factors, sugars and amino acids are said 
to inhibit aging. Caloric restriction suppresses the mTOR pathway. The activity of 
mTOR may be inhibited by rapamycin. Rapamycin has gero-suppressive effects. 
These include extending the lifespan, prevent age related disorders and reduce cost 
of patient care. AMPK activation led to an indirect inhibition of mTOR. Metformin 
acts as an AMPK activator [64, 94]. Metformin, Being an AMPK activator, met-
formin has been proved to have gero-suppressive effects. Extended longevity and 
lifespan were seen in those taking metformin. Autophagy plays a significant role 
in gero-suppressive mechanisms. Autophagy protects cell organelles and nutrient 
supply. Induction of autophagy extends the lifespan. Polyamines cause autophagy. 
Activation of autophagy induces processes associated with suppression of IGF and 
mTOR pathways. Therefore metformin acts as an activator of autophagy [95].
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1.1.8 Metformin in liver diseases
Liver dysfunction may lead to many diseases, such as diabetes, non-alcoholic 
fatty liver disease, cirrhosis, non-alcoholic hepatitis, and hepatocellular carci-
noma. Studies showed that metformin is safe in patients with cirrhosis. In diabetic 
patients, metformin caused a 50% reduction in hepatocellular carcinoma incidence 
and improved survival mainly by influencing cell growth and angiogenesis through 
the PI3K/AKT/mTOR signaling pathway [96]. In humans, metformin was also 
found to reduce the incidence of fatty liver diseases and to cause a histological 
response [97]. However, other studies showed that metformin failed to improve 
liver histology, hepatic steatosis, and inflammation [98].
1.1.9 Metformin and cardiovascular diseases
Hyperglycemia induces oxidative stress, resulting in lipoprotein dysfunction 
and endothelial dysfunction, increasing the risk of CVD. Metformin was shown to 
decrease the incidence of CVD in diabetes patients. Metformin was also shown to 
decrease irregular heartbeats and lower oxidative stress [86]. Through activating 
AMPK, metformin inhibits alpha-dicarbonyl-mediated modification of apolipopro-
tein residues, consequently ameliorating high density lipoprotein (HDL) dysfunc-
tion and reducing low density lipoprotein (LDL) modifications. Reductions in HDL 
dysfunction improve cholesterol transport and diminish the cardiovascular risk. 
Moreover, metformin improves endothelial oxidative stress levels and attenuates 
hyperglycemia-induced inflammation, decreasing the occurrence of CVD [99]. It 
has been shown that metformin improves the myocardial energy status through 
ameliorating cellular lipid and glucose metabolism via AMPK [100].
1.1.10 Metformin and renal diseases
Diabetes is considered as an important cause of renal diseases, and metformin is 
an interesting candidate to treat renal diseases, although its use was restricted pre-
viously [101]. Daily oral administration of metformin could improve kidney fibrosis 
and normalize kidney structure and function. These effects may be mediated by the 
AMPK signaling pathway, which can regulate cell growth and energy utilization. 
Another study found that in a CKD mouse model, metformin could suppress kidney 
injury and improve kidney function, through AMPK-mediated ACC signaling [102].
It is worth to note that appropriate dosage of metformin is very important in 
the treatment for renal diseases. The mechanisms underlying these kidney protec-
tive roles of metformin may be related to the regulation of glucose utilization, the 
decrease in cell inflammation, and oxidative stress [103]. The summary of met-
formin in different diseases and the underlying major mechanism is shown in the 
Figure 4.
1.2 Cons (side effects) of metformin
Metformin as all drugs, have unwanted effects which can be mild or serious side 
effects. The most common side effects are related to gut complications and include 
upset stomach, nausea, vomiting, diarrhea, light headedness, or a metallic taste in 
the mouth [104]. In general, older patients may be at an increased risk for some of 
its side effects, such as lactic acidosis or low blood sugar, due to other factors [104]. 
The minor side effects include gastrointestinal disturbances. The most common are 
anorexia, nausea, abdominal discomfort and diarrhea. Dose reduction or discontin-
uation of the drug may reduce or alleviate these symptoms. Out of the side effects, 
Metformin
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lactic acidosis and vitamin B12 deficiency happens to be the major. Although rare, 
if lactic acidosis occurs, may be fatal, which may occur in presence of hypoxia and 
renal insufficiency [105].
1.2.1 Lactic acidosis
Lactic acidosis is a condition in which lactic acid builds up in the body, altering 
pH balance and potentially leading to complications [106]. Because metformin 
reduces the breakdown of lactate to glucose, the drug may induce lactic acidosis if 
it accumulates significantly. Metformin’s exact mechanism of action in doing so is 
unknown. More frequently, the combination of this drug and an underlying health 
condition may trigger lactic acidosis [107].
The rate of developing lactic acidosis increases in patients with predisposing 
factors, such as renal impairment, hepatic disease, congestive heart failure or sepsis. 
Metformin is renally cleared. In cases of renal failure or decreased creatinine clear-
ance, metformin accumulates. When this happens, it inhibits mitochondrial electron 
transport. Therefore, it increases anerobic metabolism and lactic production [108]. 
The levels of lactate increase in metformin taking patients. The pyruvate dehydroge-
nase inhibits conversion of lactate to glucose, thereby causes lactic acidosis [109].
Because metformin decreases liver uptake of lactate, any condition that may 
precipitate lactic acidosis is a contraindication. Patients with infections, recent sur-
gery, kidney or liver damage, history of heart disease, respiratory failure, excessive 
alcohol consumption (due to depletion of NAD+ stores), or dehydration have an 
increased risk of lactic acidosis induced by metformin [110]. The FDA recommends 
avoiding the use of metformin in more severe chronic kidney disease, below the 
eGFR cutoff of 30 ml/minute/1.73 m2.
Lactate uptake by the liver is diminished with metformin use because lactate 
is a substrate for hepatic gluconeogenesis, a process that metformin inhibits. 
Metformin-associated lactate production may also take place in the large intestine, 
which could potentially contribute to lactic acidosis in those with risk factors. 
Elderly patients are also at risk for developing lactic acidosis [104, 111].
1.2.2 Vitamin B12 deficiency
A common report with long term metformin use is vitamin B12 malabsorp-
tion which leads to vitamin B12 deficiency [112, 113]. With increased metformin 
Figure 4. 
Summary of metformin in different diseases and the underlying major mechanism [103].
11
Metformin: Pros and Cons
DOI: http://dx.doi.org/10.5772/intechopen.99815
dosage, the incidence of vitamin B12 deficiency also increased [114]. In a study, it 
was proven that being treated with metformin had a 7% greater risk of vitamin B12 
deficiency than with placebo [115].
The mechanisms leading to vitamin B12 deficiency may be explained by changes 
in small intestine motility. This cause increased bacterial growth and hence, 
consumption of vitamin B12. Metformin also inhibits the calcium dependent 
absorption of vitamin B12 [116]. Vitamin B12 is an essential nutrient for cognitive 
and cardiovascular function [117, 118]. Clinical manifestations of vitamin B12 
deficiency include alteration in mental status, megaloblastic anemia and neurologi-
cal damage [118].
1.2.3 Hypoglycemia
Metformin, itself, does not lead to a state of critically low blood sugar. In combi-
nation with other risk factors such as heavy alcohol drinking (or dehydration), the 
use of other drugs for diabetes, insufficient calorie intake, or bouts of heavy exercise, 
it may increase the chances of developing hypoglycemia [100]. Since metformin does 
not directly stimulate insulin secretion, hypoglycemia risk may be lower than for that 
of other oral anti-diabetes drugs. However, hypoglycemia in patients using metfor-
min may occur in association with strenuous physical activity or fasting [119].
1.2.4 Anemia
Metformin can decrease the levels of vitamin B12 in our body. In rare cases, this 
can cause anemia or low levels of red blood cells. Metformin use is associated with 
early risk of anemia in individuals with type 2 diabetes. The mechanism for this 
early fall in hemoglobin is uncertain, but given the time course, is unlikely to be due 
to vitamin B12 deficiency alone [120].
Vitamin B12 (cobalamin) deficiency is a frequent cause of megaloblastic anemia 
that is evident through various symptoms [121]. However, the mechanism for these 
findings is unclear. Because development of anemia was not obviously associated 
with a rising mean cell volume (MCV) or macrocytosis, vitamin B12 deficiency is 
an unlikely explanation in most cases. We should evaluate anemia in metformin 
users as we would for any patient; if a thorough evaluation is unrevealing, we might 
cautiously attribute the anemia to metformin [120].
1.2.5 Cognitive impairments
A case–control study of over 7,000 patients with Alzheimer’s disease showed 
that, compared to insulin treatments, sulfonylureas, and thiazolidinediones, met-
formin was associated with an increased incidence of Alzheimer’s [122]. However, 
another study on approximately 1,500 people showed that the cognitive impairment 
associated with metformin may be alleviated with vitamin B12 and calcium supple-
ments [123]. Controversies are seen as studies have reported that metformin was 
found to significantly reduce the occurrence of cognitive dysfunction in patients 
with T2D [124]. Several studies found that metformin improved cognitive abili-
ties [125, 126]. The relationship between metformin and cognitive dysfunction in 
patients with T2D is controversial.
1.2.6 Gastrointestinal
Gastrointestinal upset is most common when metformin is first administered, 
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avoided by starting the drug at a low dose and increasing the dose gradually, but 
even with low doses, 5% of people may be unable to tolerate metformin. Long-term 
use of metformin has been associated with increased homocysteine levels and 
malabsorption of vitamin B12. Higher doses and prolonged use are associated with 
increased incidence of vitamin B12 deficiency.
2. Conclusion
Metformin, the drug initially approved and used for the treatment of Type 2 dia-
betes mellitus is proven to be effective in many other conditions such as gestational 
diabetes mellitus, obesity, hypersecretion of ovarian androgens, poly-cystic ovary 
syndrome (PCOS), anti-psychotic therapy induced weight gain, cancer treatment 
etc. There are ongoing research about the effect of metformin on anti-aging proper-
ties and proved that metformin is linked with anti-aging factors.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
13
Metformin: Pros and Cons
DOI: http://dx.doi.org/10.5772/intechopen.99815
References
[1] Bailey CJ. Metformin: historical 
overview. Diabetologia 2017; 60: 
1566-1576. doi: 10.1007/s00125-017- 
4318-z.
[2] Lucis OJ. The status of metformin in 
Canada. Canadian Medical Association 
Journal. 1983; 128(1):24-26.
[3] DeFronzo RA, Goodman AM, 
Multicenter Metformin Study Group. 
Efficacy of metformin in patients with 
non-insulin-dependent diabetes 
mellitus. N Engl J Med. 1995; 333: 
541-549.
[4] Witters LA. The blooming of the 
French lilac. J Clin Invest. 2001; 
108:1105– 7. doi: 10.1172/JCI14178.
[5] Papanagnou P, Stivarou T, Tsironi M. 
Unexploited antineo plastic effects of 
commercially available anti-diabetic 
drugs. Pharmaceuticals. 2016: 9:24. doi: 
10.3390/ph9020024.
[6] Blonde L, Dipp S, Cadena D. 
Combination glucose-lowering therapy 
plans in T2DM: case-based 
considerations. Adv Ther. 2018; 35:939-
965. doi: 10.1007/s12325-018-0694-0.




[8] Lamanna C, Monami M, 
Marchionni N, Mannucci E. Effect of 
metformin on cardiovascular events and 
mortality: a meta-analysis of 
randomized clinical trials. Diabetes 
Obes Metab. 2011; 13:221-228. doi: 
10.1111/j.1463-1326.2010.01349.x.
[9] Gandini S, Puntoni M, 
Heckman-Stoddard BM, Dunn BK, 
Ford L, Decensi A, et al. Metformin and 
cancer risk and mortality: a systematic 
review and meta-analysis taking into 
account biases and confounders. Cancer 
Prev Res. 2014; 7:867-885. doi: 
10.1158/1940-6207.CAPR-13-0424.
[10] Morales DR, Morris AD. Metformin 
in cancer treatment and prevention. 
Annu Rev Med. 2015; 66:17-29. doi: 
10.1146/annurev-med-062613-093128.
[11] Patrone C, Eriksson O, Lindholm D. 
Diabetes drugs and neurological 
disorders: new views and therapeutic 
possibilities. Lancet Diabetes 
Endocrinol. 2014; 2:256-262. doi: 
10.1016/S2213-8587(13)70125-6.
[12] Bhat A, Sebastiani G, Bhat M. 
Systematic review: preventive and 
therapeutic applications of metformin 
in liver disease. World J Hepatol. 2015; 
7:1652-1659. doi: 10.4254/wjh.v7.i12. 
1652.
[13] Breining P, Jensen JB, Sundelin EI, 
Gormsen LC, Jakobsen S, Busk M, et al. 
Metformin targets brown adipose tissue 
in vivo and reduces oxygen consumption 
in vitro. Diabetes Obes Metab. 2018; 
20:2264-2273. doi: 10.1111/dom.13362.
[14] Bannister CA , Holden SE, 
Jenkins-Jones S, Morgan CL, Halcox JP, 
Schernthaner G, Mukherjee J, Currie CJ. 
Can people with type 2 diabetes live 
longer than those without? A 
comparison of mortality in people 
initiated with metformin or 
sulphonylurea monotherapy and 
matched, non-diabetic controls. 
Diabetes Obes Metab. 2014; 16(11):1165-
1173. doi: 10.1111/dom.12354.
[15] Neven E, Vervaet B, Brand K, 
Gottwald-Hostalek U, Opdebeeck B, De 
Mare A, et al. Metformin prevents the 
development of severe chronic kidney 
disease and its associated mineral and 
bone disorder. Kidney Int. 2018; 94:102-
113. doi: 10.1016/j.kint.2018.01.027





htm. Accessed on May 23, 2017.
[17] Ng TP, Feng L, Yap KB, Lee TS, 
Tan CH, Winblad B. Long-term 
metformin usage and cognitive function 
among older adults with diabetes. J 
Alzheimers Dis. 2014; 41(1):61-68. doi: 
10.3233/JAD-131901.
[18] Alam U, Asghar O, Azmi S , 
Malik RA. General aspects of diabetes 
mellitus. Handb Clin Neurol. 2014; 
126:211-222. doi: 10.1016/B978-0- 
444-53480-4.00015-1.
[19] Bailey CJ, Turner RC. Metformin. N 
Engl J Med. 1996; 334(9):574-579. doi: 
10.1056/NEJM199602293340906.
[20] Shaw RJ, Lamia KA, Vasquez D, 
Koo SH, Bardeesy N, Depinho RA, et al. 
The kinase LKB1 mediates glucose 
homeostasis in liver and therapeutic 
effects of metformin. Science. 2005; 
310:1642-1646. doi: 10.1126/science. 
1120781.
[21] Fullerton MD, Galic S, Marcinko K, 
Sikkema S, Pulinilkunnil T, Chen ZP, et 
al. Single phosphorylation sites in Acc1 
and Acc2 regulate lipid homeostasis and 
the insulin-sensitizing effects of 
metformin. Nat Med. 2013; 19:1649-
1654. doi: 10.1038/nm.3372.
[22] Foretz M, Hebrard S, Leclerc J, 
Zarrinpashneh E, Soty M, Mithieux G, 
et al. Metformin inhibits hepatic 
gluconeogenesis in mice independently 
of the LKB1/AMPK pathway via a 
decrease in hepatic energy state. J Clin 
Invest. 2010; 120:2355-2369. doi: 
10.1172/JCI40671.
[23] Madiraju AK, Erion DM, Rahimi Y, 
Zhang XM, Braddock DT, Albright RA, 
Prigaro BJ, Wood JL, Bhanot S, 
MacDonald MJ, Jurczak MJ, 
Camporez JP, Lee HY, Cline GW, 
Samuel VT, Kibbey RG, Shulman GI. 
Metformin suppresses gluconeogenesis 
by inhibiting mitochondrial 
glycerophosphate dehydrogenase. 
Nature. 2014; 510(7506):542-546. doi: 
10.1038/nature13270.
[24] Gaochao Zhou, Robert Myers, Ying 
Li, Yuli Chen, Xiaolan Shen, Judy 
Fenyk-Melody, Margaret Wu, John 
Ventre, Thomas Doebber, Nobuharu 
Fujii, Nicolas Musi, Michael F. 
Hirshman, Laurie J. Goodyear, and 
David E. Moller. Role of AMP-activated 
protein kinase in mechanism of 
metformin action. J Clin Invest. 2001; 
108(8):1167-1174. https://doi.
org/10.1172/JCI13505.
[25] Dumitrescu R, Mehedintu C, 
Briceag I, Purcarea VL, and Hudita D. 
Metformin-Clinical Pharmacology in 
PCOs. J Med Life. 2015; 8(2): 
187-192.
[26] He L, Sabet A, Djedjos S, Miller R, 
Sun X, Hussain MA, et al. Metformin 
and insulin suppress hepatic 
gluconeogenesis through 
phosphorylation of CREB binding 
protein. Cell. 2009; 137:635-646. doi: 
10.1016/j.cell.2009.03.016.
[27] Herzig S, Long F, Jhala US, 
Hedrick S, Quinn R, Bauer A, et al. 
CREB regulates hepatic gluconeogenesis 
through the coactivator PGC-1. Nature. 
2001; 413:179-183. doi: 
10.1038/35093131.
[28] Gunton JE, Delhanty PJ, 
Takahashi S, Baxter RC. Metformin 
rapidly increases insulin receptor 
activation in human liver and signals 
preferentially through insulin-receptor 
substrate-2. J Clin Endocrinol Metab. 
2003; 88:1323-1332. doi: 10.1210/
jc.2002-021394.
[29] Kristensen JM, Treebak JT, 
Schjerling P, Goodyear L, 
Wojtaszewski JF. Two weeks of 
metformin treatment induces AMPK-
dependent enhancement of insulin-
stimulated glucose uptake in mouse 
soleus muscle. Am J Physiol Endocrinol 
15
Metformin: Pros and Cons
DOI: http://dx.doi.org/10.5772/intechopen.99815
Metab. 2014; 306:E1099–E1109. doi: 
10.1152/ajpendo.004 17.2013.
[30] Gu S, Shi J, Tang Z, Sawhney M, 
Hu H, Shi L, et al. Comparison of 
glucose lowering effect of metformin 
and acarbose in type 2 diabetes mellitus: 
a metaanalysis. PLoS ONE. 2015; 
10:e0126704. doi: 10.1371/journal.
pone.0126704.
[31] Emilie Bahne, Emily W. L. Sun, 
Richard L. Young, Morten Hansen, 
David P. Sonne, Jakob S. Hansen, Ulrich 
Rohde, Alice P. Liou, Margaret L. 
Jackson, Dayan de Fontgalland, Philippa 
Rabbitt, Paul Hollington, Luigi Sposato, 
Steven Due, David A. Wattchow, Jens F. 
Rehfeld, Jens J. Holst, Damien J. Keating, 
Tina Vilsbøll, and Filip K. Knop. 
Metformin-induced glucagon-like 
peptide-1 secretion contributes to the 
actions of metformin in type 2 diabetes. 
JCI Insight. 2018; 3(23): e93936.
[32] He L, Wondisford FE. Metformin 
action: concentration matters. Cell 
Metab. 2015; 21(2):159-162. doi: 
10.1016/j.cmet.2015.01.003
[33] Nolte Kennedy MS, Masharani U: 
Pancreatic Hormones & Antidiabetic 
Drugs (Chapter 41). In: Basic & Clinical 
Pharmacology. 15th Ed. Katzung BG, 
Trevor AJ (Editors). McGraw-Hill / 
Lange.2015
[34] Diabetes Prevention Program 
Research Group. Reduction In The 
Incidence Of Type 2 Diabetes With 
Lifestyle Intervention Or Metformin. N 
Engl J Med. 2002; 346(6):393-403. doi: 
10.1056/NEJMoa012512.
[35] Classification and diagnosis of 
diabetes mellitus and other categories of 
glucose intolerance. National Diabetes 
Data Group. Diabetes. 1979; 
(12):1039-1057.
[36] World Health Organization. 
Diagnostic criteria and classification of 
hyperglycaemia first detected in 
pregnancy. Geneva (CH): World Health 
Organization; 2013. Available from: 
http: //130.14.29.110/books/NBK169024.
[37] Dall, T. M., Yang, W., Halder, P., 
Pang, B., Massoudi, M., Wintfeld, N.,  
et al. The economic burden of elevated 
blood glucose levels in 2012: diagnosed 
and undiagnosed diabetes, gestational 
diabetes mellitus, and prediabetes. 
Diabetes Care. 2014; 37(12):3172-3179. 
doi: 10.2337/dc14-1036.
[38] Farrar, D., Simmonds, M., Bryant, 
M., Sheldon, T. A., Tuffnell, D., Golder, 
S., et al. Treatments for gestational 
diabetes: a systematic review and 
meta-analysis. BMJ Open. 2017; 
7(6):e015557. doi: 10.1136/bmjopen- 
2016-015557.
[39] Catalano PM, Tyzbir ED, 
Roman NM, Amini SB, Sims EA. 
Longitudinal changes in insulin release 
and insulin resistance in nonobese 
pregnant women. Am J Obstet Gynecol. 
1991; 165:1667-1672.
[40] Rena G, Hardie DG, Pearson ER. 
The mechanisms of action of 
metformin.Diabetologia. 2017; 
60(9):1577-1585.
[41] Eyal S, Easterling TR, Carr D, 
Umans JG, Miodovnik M, Hankins GD, 
Clark SM, Risler L, Wang J, Kelly EJ, 
Shen DD, Hebert MF. Pharmacokinetics 
of metformin during pregnancy. Drug 
Metab Dispos. 2010; 38(5):833-840.
[42] Nawaz FH, Khalid R, Naru T, 
Rizvi J. Does continuous use of 
metformin throughout pregnancy 
improve pregnancy outcomes in women 
with polycystic ovarian syndrome? J 
Obstet Gynaecol Res. 2008; 34(5): 
832-837.
[43] Bolton S, Cleary B, Walsh J, 
Dempsey E, Turner MJ. Continuation of 
metformin in the first trimester of 
women with polycystic ovarian 
syndrome is not associated with 
Metformin
16
increased perinatal morbidity. Eur J 
Pediatr. 2009; 168(2):203-206.
[44] Rowan JA, Hague WM, Gao W, 
Battin MR, Moore MP, MiG Trial 
Investigators. Metformin versus insulin 
for the treatment of gestational 
diabetes. N Engl J Med. 2008; 
358(19):2003-2015.
[45] Gui, J, Liu Q, Feng L. Metformin vs 
insulin in the management of 
gestational diabetes: a meta-analysis. 
PloS One. 2013; 8(5), e64585. doi: 
10.1371/journal.pone.0064585.
[46] Romero R., Erez O, Huttemann M, 
Maymon E, Panaitescu B, 
Conde-Agudelo A, et al. Metformin, the 
aspirin of the 21st century: its role in 
gestational diabetes mellitus, prevention 
of preeclampsia and cancer, and the 
promotion of longevity. Am. J. Obstet. 
Gynecol. 2017; 217 (3): 282-302. doi: 
10.1016/j.ajog.2017.06.003.
[47] Dunaif A, Segal KR., Futterweit W, 
Dobrjansky A. Profound peripheral 
insulin resistance, independent of 
obesity, in polycystic ovary syndrome. 
Diabetes. 1989; 38 (9), 1165-1174. doi: 
10.2337/diab.38.9.1165.
[48] Franks S. Polycystic ovary 
syndrome. N. Engl. J. Med. 1995; 
333(13): 853-861. doi: 10.1056/
NEJM199509283331307.
[49] Holte, J. Disturbances in insulin 
secretion and sensitivity in women with 
the polycystic ovary syndrome. 
Baillieres Clin. Endocrinol. Metab. 1996; 
10(2): 221-247. doi: 10.1016/
S0950-351X(96)80085-1.
[50] Lathief S and Pal L. Advances in 
Treatment options for Polycystic 
Ovarian Syndrome. Female 
Endocrinology. US Endocrinology. 2012; 
8(1):57-64.
[51] Hsin-Shih W. The Role of Metformin 
in the Treatment of Polycystic Ovarian 
Syndrome (PCOS). Forum. Chang Gung 
Med J. 2006; 29(5):445-447.
[52] Spritzer PM. PCOS: Reviewing 
Diagnosis and Management of 
Metabolic Disturbances. Arq Bras 
Endocrinal Metab. 2014; 58 (2):  
182-187.
[53] Despres JP, Lemieux I. Abdominal 
obesity and metabolic syndrome. 
Nature. 2006; 444:881-887. doi: 10.1038/
nature05488.
[54] Aa MP, Hoving V, Garde EMW, 
Boer A, Knibbe CAT, Vorst MMJ. The 
Effect of Eighteen- Month Metformin 
Treatment in Obese Adolscents: 
Comparison of Results Obtained in 
Daily Practice with Results from a 
Clinical Trial. Journal of Obesity. 2016; 
2016: 1-7.
[55] Karise I, Bargut TC, Del Sol M, 
Aguila MB, Mandarim-De-Lacerda CA. 
Metformin enhances mitochondrial 
biogenesis and thermogenesis in brown 
adipocytes of mice. Biomed 
Pharmacother. 2019; 111:1156-1165. doi: 
10.1016/j.biopha.2019.01.021.
[56] Kirpichnikov D, McFarlane SI, 
Sowers JR. Metformin: an update. Ann 
Intern Med. 2002; 137:25-33.
[57] Caprio S. Treatment of impaired 
glucose tolerance in childhood. Nat Clin 
Pract Endocrinol Metab 2008; 
4:320-332;
[58] McDonagh MS, Selph S, Ozpinar A, 
Foley C. Systematic review of the 
benefits and risks of metformin in 
treating obesity in children aged 18 
years and younger. JAMA Pediatr. 2014; 
168(2):178-184.
[59] Graff SK, Mario FM, Ziegelmann P, 
Spritzer PM. Effects of orlistat vs. 
metformin on weight loss-related 
clinical variables in women with PCOS: 
systematic review and meta-analysis. Int 
J Clin Pract. 2016; 70(6):450-461.
17
Metformin: Pros and Cons
DOI: http://dx.doi.org/10.5772/intechopen.99815
[60] Hostalek U, Gwilt M, Hildemann S. 
Therapeutic Use of Metformin in 
Prediabetes and Diabetes Prevention. 
Drugs. 2015; 75(10):1071-1094.
[61] Fenton WS and Chavez MR. 
Medication Induced Weight Gain and 
Dyslipidemia in Patients with 
Schizophrenia. Am J Psychiatry. 2016; 
163(10): 1697-1704.
[62] Generali JA and Cada DJ. Off- Label 
Drug Uses, Metformin: Prevention and 
Treatment of Antipsychotic-Induced 
Weight Gain. Hosp Pharm. 2013; 48(9): 
734-735.
[63] Fenton WS and Chavez MR. 
Medication Induced Weight Gain and 
Dyslipidemia in Patients with 
Schizophrenia. Am J Psychiatry. 2016; 
163(10): 1697-1704.
[64] Podhorecka M, Ibanez B, 
Dmoszynska A. Metformin – its 
potential anticancer and anti-aging 
effects. Postepy Hig, Medycyny 
Doswiadczalnej. 2017; 71: 170-175. doi: 
10.5604/01.3001.0010.3801.
[65] Gwinn DM, Shackelford DB, 
Egan DF, MihaylovaMM, Mery A, 
Vasquez DS, et al. AMPK 
phosphorylation of raptor mediates a 
metabolic checkpoint.Mol Cell. 2008; 
30:214-226. doi: 10.1016/j.
molcel.2008.03.003.
[66] Sui X, Xu Y, Wang X, Han W, 
Pan H, Xiao M. Metformin: a novel but 
controversial drug in cancer prevention 
and treatment. Mol Pharm. (2015) 
12:3783-3791. doi: 10.1021/acs.
molpharmaceut.5b00577.
[67] Pryor R, Cabreiro F. Repurposing 
metformin: an old drug with new tricks 
in its binding pockets. Biochem J. 2015; 
471:307-322. doi: 10.1042/BJ20150497.
[68] MoiseevaO, Deschenes-Simard X, 
St-Germain E, Igelmann S, HuotG, 
Cadar AE, et al. Metformin inhibits the 
senescence-associated secretory 
phenotype by interfering with IKK/
NF-kappaB activation. Aging Cell. 
(2013) 12:489-98, doi: 10.1111/
acel.12075.
[69] Cerezo M, Tichet M, Abbe P, 
Ohanna M, Lehraiki A, Rouaud F, et al. 
Metformin blocks melanoma invasion 
and metastasis development in AMPK/
p53-dependent manner. Mol Cancer 
Ther. 2013; 12:1605-1615. doi: 
10.1158/1535-7163.MCT-12-1226-T.
[70] Ugwueze CV, Ogamba OJ, 
Young EE, Onyenekwe BM and 
Ezeokpo BC. Metformin: A Possible 
Option in Cancer Chemotherapy. 
Analytical Cellular Pathology. 2020; 
https://doi.org/10.1155/2020/7180923.
[71] Rego DF, Pavan LM, Elias ST, De 
Luca Canto G, Guerra EN. Effects of 
metformin on head and neck cancer: a 
systematic review. Oral Oncol. 2015; 
51(5):416-422.
[72] Kasznicki J, Sliwinska A, 
Drzewoski J. Metformin in cancer 
prevention and therapy. Ann Transl 
Med. 2014; 2:57. doi: 10.3978/j.
issn.2305-5839.2014.06.01.
[73] Dowling R, Niraula S, Stambolic V, 
Goodwin P. Metformin in cancer: 
translational challenges. Journal of 
molecular endocrinology 2012; 
DOI:10.1530/JME-12-007
[74] Dowling RJ, Goodwin PJ, 
Stambolic V. Understanding the benefit 
of metformin use in cancer treatment. 
BMC Med 9: 33. Available at http://
www.biomedcentral.com/1741-7015/ 
9/33
[75] Polak R, Buitenhuis M. The PI3K/
PKB signaling module as key regulator 
of hematopoiesis: implications for 
therapeutic strategies in leukemia. 




[76] Shi WY, Xiao D, Wang L, Dong LH, 
Yan ZX, Shen ZX, et al. Therapeutic 
metformin/AMPK activation blocked 
lymphoma cell growth via inhibition of 
mTOR pathway and induction of 
autophagy. Cell Death Dis. 2012; 3:e275.
doi: 10.1038/cddis.2012.13.
[77] Yang YX, Hennessy S, Lewis JD. 
Insulin therapy and colorectal cancer 
risk among type 2 diabetes mellitus 
patients. Gastroenterology. 2004; 
127:1044-1050. doi: 10.1053/j.
gastro.2004.07.011.
[78] Mccreight LJ, Bailey CJ, Pearson ER. 
Metformin and the gastrointestinal 
tract. Diabetologia. 2016; 59:426-435. 
doi: 10.1007/s00125-015-3844-9.
[79] Linnard-Palmer L. The use of 
simulation for pediatric oncology 
nursing safety principles: ensuring 
competent practice through the use of a 
mnemonic, chemotherapy road maps 
and case-based learning. J Pediatr Nurs. 
2012; 27:283-286. doi: 10.1016/j.
pedn.2012.02.001.
[80] Mundy GR. Metastasis to bone: 
causes, consequences and therapeutic 
opportunities. Nat Rev Cancer. 2002; 
2:584-593. doi: 10.1038/nrc867.
[81] Ko EM, Walter P, Jackson A, 
Clark L, Franasiak J, Bolac C, et al. 
Metformin is associated with improved 
survival in endometrial cancer. Gynecol 
Oncol. 2014; 132:438-442. doi: 10.1016/j.
ygyno.2013.11.021.
[82] Demierre MF. Epidemiology and 
prevention of cutaneous melanoma. 
Curr Treat Options Oncol. 2006; 
7:181-186. doi: 10.1007/
s11864-006-0011-z.
[83] Li K, Zhang TT, Wang F, Cui B, 
Zhao CX, Yu JJ, et al. Metformin 
suppresses melanoma progression by 
inhibiting KAT5-mediated SMAD3 
acetylation, transcriptional activity and 
TRIB3 expression. Oncogene. 2018; 
37:2967-2981. doi: 10.1038/
s41388-018-0172-9.
[84] Losordo DW, Henry TD. New 
definition of aging? Measuring 
regenerative capacity in patients. Circ 
Res. 2016; 119:774-775. doi: 10.1161/
CIRCRESAHA.116.309622.
[85] Hoeijmakers JH. DNA damage, 





[87] Soukas AA, Hao H, Wu L. 
Metformin as Anti-Aging Therapy: Is It 
for Everyone? Trends Endocrinol Metab. 
2019; 30(10):745-755. doi: 10.1016/j.
tem.2019.07.015.
[88] Algire C, Moiseeva O, 
Deschenes-Simard X, Amrein L, 
Petruccelli L, Birman E, et al. 
Metformin reduces endogenous reactive 
oxygen species and associated DNA 
damage. Cancer Prev Res. 2012; 5:536-
543.doi: 10.1158/1940-6207.
CAPR-11-0536.
[89] Valencia WM, Palacio A, Tamariz L, 
Florez H. Metformin and ageing: 
improving ageing outcomes beyond 
glycaemic control. Diabetologia. 2017; 
60:1630-1638. doi: 10.1007/
s00125-017-4349-5.
[90] Song YM, Lee YH, Kim JW, 
Ham DS, Kang ES, Cha BS, et al. 
Metformin alleviates hepatosteatosis by 
restoring SIRT1-mediated autophagy 
induction via an AMP-activated protein 
kinase-independent pathway. 
Autophagy. 2015; 11:46-59. doi: 
10.4161/15548627.2014.984271.
[91] Barzilai N, Crandall JP, 
Kritchevsky SB, EspelandMA. 
Metformin as a tool to target aging. Cell 
Metab. 2016; 23:1060-1065. doi: 
10.1016/j.cmet.2016.05.011.
19
Metformin: Pros and Cons
DOI: http://dx.doi.org/10.5772/intechopen.99815
[92] Arora BP. Anti-aging Medicine. 
Indian J. Plastic Surgery Supplement. 
2008; 41: S130-S133.
[93] Foretz M, Guigas B, Bertrand L, 
Pollak M, Viollet B. Metformin: From 
Mechanism of Action to Therapies. Cell 
Metabolism 20. 2014; 20(6):953-966.
[94] Hawley SA, Gadalla AE, Olsen GS, 
Hardie DG. The Antidiabetic Drug 
Metformin Activates the AMP-Activated 
Protein Kinase Cascade via an Adenine 
Nucleotide- Independent Mechanism. 
Diabetes. 2002; 51: 2420-2425.
[95] Menendez JA, Cufi S, 
Oliveras-Ferraros C, Vellon L, Joven J, 
Vazquez-Martin A. Gerosuppressant 
Metformin: less is more. Aging. 2011; 
3(4): 348- 362.
[96] Singh S, Singh PP, Singh AG, 
Murad MH, Sanchez W. Anti-diabetic 
medications and the risk of 
hepatocellular cancer: a systematic 
review and meta-analysis. Am J 
Gastroenterol. 2013; 108:881-891. doi: 
10.1038/ajg.2013.5.
[97] Lavine JE, Schwimmer JB, Van 
Natta ML, Molleston JP, Murray KF, 
Rosenthal P, et al. Effect of vitamin E or 
metformin for treatment of 
nonalcoholic fatty liver disease in 
children and adolescents: the TONIC 
randomized controlled trial. JAMA. 
2011; 305:1659-1668. doi: 10.1001/
jama.2011.520.
[98] Tiikkainen M, Hakkinen AM, 
Korsheninnikova E, Nyman T, 
Makimattila S, Yki-Jarvinen H. Effects 
of rosiglitazone and metformin on liver 
fat content, hepatic insulin resistance, 
insulin clearance, and gene expression 
in adipose tissue in patients with type 2 
diabetes. Diabetes. 2004; 53:2169-2176. 
doi: 10.2337/diabetes.53.8.2169.
[99] Kheniser KG, Kashyap SR, 
Kasumov T. A systematic review: the 
appraisal of the effects of metformin on 
lipoprotein modification and function. 
Obes Sci Pract. 2019; 5:36-45. doi: 
10.1002/osp4.309.
[100] Dziubak A, Wojcicka G, Wojtak A, 
Beltowski J. Metabolic effects of 
metformin in the failing heart. Int J Mol 
Sci. 2018; 19:2869. doi: 10.3390/
ijms19102869.
[101] Misbin RI, Green L, Stadel BV, 
Gueriguian JL, Gubbi A, Fleming GA. 
Lactic acidosis in patients with diabetes 
treated with metformin. N Engl J Med. 
1998; 338:265-266. doi: 10.1056/
NEJM199801223380415.
[102] Lee M, Katerelos M, Gleich K, 
Galic S, Kemp BE, Mount PF, et al. 
Phosphorylation of Acetyl-CoA 
Carboxylase by AMPK Reduces Renal 
Fibrosis and Is Essential for the Anti-
Fibrotic Effect of Metformin. J Am Soc 
Nephrol. 2018; 29:2326-36. doi: 0.1681/
ASN.2018010050.
[103] Lv Z and Guo Y (2020) Metformin 
and Its Benefits for Various Diseases. 
Front. Endocrinol. 2020; 11:191. doi: 
10.3389/fendo.2020.00191.
[104] Hamid Nasri and Mahmoud 
Rafieian-Kopaei. Metformin: Current 
knowledge. J Res Med Sci. 2014; 
19(7):658-664.
[105] Suh S. Metformin- Associated 
Lactic Acidosis. Endocrinology 
Metabolism. 2015; 30:45-46.
[106] Jeffrey KA and Nicolaos EM. Lactic 
acidosis. The New England journal of 
medicine, 371(24): 2309-2319. 
Doi.10.1056/nejmra1309483.
[107] Lalau JD, Kajbaf F, Protti A, 
Christensen MM, De Broe ME, 
Wiernsperger N. Metformin-associated 
lactic acidosis (MALA): Moving towards 
a new paradigm. Diabetes Obes Metab. 




[108] Misbin RI. The Phantom of Lactic 
Acidosis due to Metformin in Patients 
with Diabetes. Diabetes Care. 2004; 
27(7):1791-1793.
[109] Renda F, Mura P, Finco G, 
Ferrazin F, Pani L, Landoni G. 
Metformin- Associated Lactic Acidosis 
Requiring Hospitalization. A National 
10 year Survey and a Systematic 
Literature Review. European Review for 
Medical and Pharmacological Sciences. 
2013; 17(Supplement 1):45-49.
[110] Yazdi P. 9 Proven Metformin Uses + 
Side Effects. 2020; Available at https://
selfhacked.com/blog/uses-benefits-
metformin/#Side_Effects_of_
Metformin. Accessed on 20 June 2021.
[111] Scheen AJ, Paquot N. Metformin 
revisited: a critical review of the benefit-
risk balance in at-risk patients with type 
2 diabetes. Diabetes Metab. 2013; 
39(3):179-190. doi: 10.1016/j.
diabet.2013.02.006.
[112] Kumthekar AA, Gidwani HV, 
Kumthekar AB. Metformin Associated 
B12 deficiency. JAPI. 2012; 60: 58-59.
[113] Kang D, Yun JS, Ko SH, Lim TS, 
Ahn YB, Park YM, Ko HS. Higher 
Prevalence of Metformin-Induced 
Vitamin B12 Deficiency in Sulfonylurea 
Compared with Insulin Combination in 
Patients with Type 2 Diabetes: A 
Cross- Sectional Study. PLoS ONE. 
2014; 9(10):1-9.
[114] Liu Q, Li S, Quan H, Li J. Vitamin 
B12 status in metformin treated 
patients: systematic review. PLoS One. 
2014; 9(6):e100379. doi: 10.1371/journal.
pone.0100379.
[115] Jager J, Kooy A, Lehert P, 
Wulffele MG, Kolk J, Bets D, Verburg J, 
Donker AJM, Stehouwer CDA. Long Term 
Treatment with Metformin in Patients 
with Type 2 Diabetes and Risk of Vitamin 
B12 Deficiency: Randomised Placebo 
Controlled Trial. BMJ. 2010; 340:1-7.
[116] Jeetendra S and Tushar B. 
Metformin Use and Vitamin B12 
Deficiency in Patients with Type 2 
Diabetes Mellitus. MVP Journal of 
Medical Sciences. 2016; 3(1):67-70
[117] Kibirige D and Mwebaze R. 
Vitamin B12 Deficiency among Patients 
with Diabetes Mellitus: Is Routine 
Supplementation Justified? Diabetes 
and Metabolic Disorders. 2013; 
12(17):1-6.
[118] Fatima S and Noor S. A Review on 
Effects of Metformin on Vitamin B12 
Status. American Journal of 
Phytomedicine and Clinical 
Therapeutics. 2013; 1(8):652-660.
[119] Bodmer M, Meier C, Krahenbuhl S, 
Jick SS, Meier CR. Metformin, 
Sulfonylureas, or Other Antidiabetes 
Drugs and the Risk of Lactic Acidosis or 
Hypoglycemia. A nested case-control 
analysis. Diabetes Care. 2008; 
31(11):2086-2091. https://doi.
org/10.2337/dc08-1171.
[120] Donnelly LA, Dennis JM, 
Coleman RL, Sattar N, Hattersley AT, 
Holman RR, Pearson ER. Risk of 
Anemia with Metformin Use in Type 2 
Diabetes: A MASTERMIND Study. 
Diabetes Care. 2020; dc201104.https://
doi.org/10.2337/dc20-1104.
[121] Fujita H, Narita T, Yoshioka N, et 
al. A case of megaloblastic anemia due 
to vitamin B12 deficiency precipitated in 
a totally gastrectomized type II diabetic 
patient following the introduction of 
metformin therapy. Endocr J. 2003; 
50(4):483-484. doi:10.1507/
endocrj.50.483.
[122] Patrick Imfeld, Michael Bodmer, 
Susan S Jick, Christoph R Meier. 
Metformin, other antidiabetic drugs, 
and risk of Alzheimer's disease: a 
population-based case-control study J 




Metformin: Pros and Cons
DOI: http://dx.doi.org/10.5772/intechopen.99815
[123] Moore EM , Mander AG, Ames D, 
Kotowicz MA, Carne RP, Brodaty H, 
Woodward M, Boundy K, Ellis KA, 
Bush AI, Faux NG, Martins R, Szoeke C, 
Rowe C, Watters DA, AIBL 
Investigators. Increased risk of cognitive 
impairment in patients with diabetes is 
associated with metformin. Diabetes 
Care. 2013; 36(10):2981-2987. doi: 
10.2337/dc13-0229.
[124] Qing ZQ, Shan LW, Zhou L; Zhang, 
Li HZ, Gui BY, Xia ZR. Metformin 
therapy and cognitive dysfunction in 
patients with type 2 diabetes. A meta-
analysis and systematic review. 
Medicine: 2020; 99(10):p e19378. doi: 
10.1097/MD.0000000000019378.
[125] Yokoyama H, Ogawa M, Honjo J,  
et al. Risk factors associated with 
abnormal cognition in Japanese 
outpatients with diabetes, hypertension 
or dyslipidemia. Diabetol Int 2015; 
6:268-274.
[126] Zhou Y, Fang R, Liu LH, et al. 
Clinical characteristics for the 
relationship between type-2 diabetes 
mellitus and cognitive impairment: a 
cross-sectional study. Aging Dis 2015; 
6:236-244.
